We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Screening Test Recommended for Heritable Blood Disorder

By LabMedica International staff writers
Posted on 17 Mar 2011
A blood test has been recommended for screening newborns or infants for all forms of an inherited blood disorders as this may reduce morbidity. More...


The hemoglobinopathy is known as Hemoglobin H disease or Alpha Thalassemia and is diagnosed by a variety of tests including high performance liquid chromatography (HPLC). Samples containing more than 25% hemoglobin Bart's should be selected for confirmatory testing.

Over a 15-year period, scientists at the Children's Hospital Oakland, (CA, USA), observed and tested 86 patients, of whom 23 had hemoglobin H Constant Spring mutation (HCS). Diagnosis was confirmed by thin-layer isoelectric focusing, and specific α-globin gene deletions or mutations were identified by multiplexed gap-polymerase-chain-reaction assay. Patients with hemoglobin H have moderately severe anemia because of gene defects leading to insufficient production of hemoglobin. The disorder does not usually cause significant health problems, except in cases of HCS, a severe form of the disease, which often results in life-threatening anemia.

The study provided a previously undocumented natural history of the disease in young children. The patients with HbH exhibited relatively normal growth and development without needing blood transfusions, but patients with HCS were at high-risk for life-threatening anemia even during infancy. There were significant differences in hemoglobin levels between the HbH group and the HCS group and the absolute reticulocyte count and bilirubin level were consistently higher in patients with HCS.

A diagnosis of HCS avoids expending precious time, which could save a young life and money trying to diagnose the problem. The study also demonstrated that hemoglobin H is not restricted to the traditional Asian ethnic populations. Although 81% patients studied had an Asian background, 5% were Hispanic, 3% were African American, and 10% had mixed ancestry.

The study shows that the advanced DNA testing at Children's Hospital Oakland can predict the course of the disease during childhood, which helps to ensure proper treatment for all patients. Hemoglobin H disease arises from the deletion of three of four α-globin genes and HCS is caused by the deletion of two α-globin genes and the Constant Spring mutation. In California, one in 10,000 newborns is diagnosed with hemoglobin H disease. The study was published on February 24, 2011, in the New England Journal of Medicine (NEJM).

Related Links:
Children's Hospital Oakland




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.